Advances in Purification and Recovery | August 12-13, 2026

Advances in Purification & Recovery

Optimizing Downstream Efficiency

8/12/2026 - August 13, 2026 ALL TIMES EDT

The Advances in Purification & Recovery conference tackles critical purification challenges across advanced antibodies such as bispecifics and ADCs, as well as emerging modalities like mRNA, AAV, oligos, and exosomes. Explore AI-assisted chromatography optimization, next-generation filtration for high-titer challenges, continuous multi-column systems, and real-time PAT integration. Whether youâ€™re developing platform purification strategies, implementing mechanistic modeling to accelerate timelines, or driving COGS reduction through process intensification, you'll gain actionable insights from industry experts transforming purification into a competitive advantage.

Preliminary Agenda

Session Block

PLENARY SESSION

PLENARY KEYNOTE PRESENTATION:
The Correct Way to Bring Digital and AI into Biopharmaceutical Quality

Photo of Anthony R. Mire-Sluis, PhD, Senior Vice President, Global Quality, Gilead Sciences , SVP , Global Quality , Gilead Sciences — Anthony R. Mire-Sluis, PhD, Senior Vice President, Global Quality, Gilead Sciences , SVP , Global Quality , Gilead Sciences

Digitalizing quality systems and the advent of artificial intelligence has the potential to revolutionize the way we work in quality. However, it needs careful planning and execution to gain the maximum benefits to the business. Appropriate use cases, change management, training, and streamlining processes before you digitalize is essentialâ€”putting complexity in just results in digital complexity. In addition, the implementation of AI must follow GxP principles in what is currently a vague regulatory framework.

Panel Moderator:

FIRESIDE CHAT: Bringing Digital and AI into Biopharmaceutical Quality and Manufacturing

Photo of Susan Hynes, Global Head of Quality, GSK , SVP, GSK Global Quality , GSK — Susan Hynes, Global Head of Quality, GSK , SVP, GSK Global Quality , GSK

Panelists:

Photo of Lynn Bottone, Senior Vice President, Quality Operations, Environment Health & Safety, Pfizer Inc. , Senior Vice President Quality, Safety & Environmental Operations , Quality Operations, Environment Health & Safety , Pfizer Inc — Lynn Bottone, Senior Vice President, Quality Operations, Environment Health & Safety, Pfizer Inc. , Senior Vice President Quality, Safety & Environmental Operations , Quality Operations, Environment Health & Safety , Pfizer Inc

Session Block

PURIFICATION FOR EMERGING MODALITIES

Low Molecular Weight (LMW) Species Control in Bispecific Antibody Purification Process

Photo of Lingling Xia, PhD, Principal Research Scientist I, Purification Process Developmentâ€”ADC, PDS&T-BDL, AbbVie Inc. , Principal Research Scientist I, Purification Process Development - ADC , PDS&T - BDL , AbbVie Inc — Lingling Xia, PhD, Principal Research Scientist I, Purification Process Developmentâ€”ADC, PDS&T-BDL, AbbVie Inc. , Principal Research Scientist I, Purification Process Development - ADC , PDS&T - BDL , AbbVie Inc

Photo of Yanhuai (Richard) Ding, PhD, Senior Director, CMC DS/DP, EvolveImmune Therapeutics , Sr. Director, CMC DS/DP , CMC , EvolveImmune Therapeutics — Yanhuai (Richard) Ding, PhD, Senior Director, CMC DS/DP, EvolveImmune Therapeutics , Sr. Director, CMC DS/DP , CMC , EvolveImmune Therapeutics

Photo of Albert Kao, Senior Scientist, Purification Development, Genentech, Inc. , Senior Scientist , Purification Development , Genentech, Inc. — Albert Kao, Senior Scientist, Purification Development, Genentech, Inc. , Senior Scientist , Purification Development , Genentech, Inc.

Photo of Tomas Mesurado, PhD Student, Acib GmbH , PhD Student , Bioprocess Engineering , Acib GmbH — Tomas Mesurado, PhD Student, Acib GmbH , PhD Student , Bioprocess Engineering , Acib GmbH

Photo of Rujin Cheng, PhD, Principal Scientist, Biotherapeutics, ImmunEdge , Principal Scientist , Biotherapeutics , ImmunEdge — Rujin Cheng, PhD, Principal Scientist, Biotherapeutics, ImmunEdge , Principal Scientist , Biotherapeutics , ImmunEdge

Hexameric IgGs are a class of complex biologics that offers unique pharmacokinetics and pharmacodynamic properties due to their high valency (up to 12 antigen binding sites), molecular weight (~900 kDa), or hydrodynamic radius. Despite their attractive profile for certain therapeutic indications, technical challenges in purification and analytics hinder their broader application. This talk aims to demystify some of the challenges by providing comprehensive molecule analysis/illustration and a couple of successful examples where key problems are identified and resolved. It would be of some guidance or introduction for those who are interested in making large and complex biologics for drug discovery and development.

NEXT-GENERATION CHROMATOGRAPHY

KEYNOTE PRESENTATION:Â Next-Generation Cation Exchange Chromatography Platform Process Development for Biologics Purification

Photo of Lihua Yang, PhD, Principal Research Scientist II, Mfg Sciences, AbbVie Inc. , Senior Principal Research Scientist , Mfg Sciences , AbbVie Inc — Lihua Yang, PhD, Principal Research Scientist II, Mfg Sciences, AbbVie Inc. , Senior Principal Research Scientist , Mfg Sciences , AbbVie Inc

This study evaluated five cation exchange (CEX) resins using three mAbs to identify optimal resins and develop a CEX process with superior dynamic binding capacity (DBC), impurity clearance, recovery yield, and robustness. In addition to experimental approaches, a mechanistic model was utilized to streamline the programming process as well as offering the potential to significantly reduce or even replace labor-intensive laboratory experiments in future process development.

Chromatographic Control of dsRNA Impurities Using a Mixed Mode Method with Platform Potential

Photo of Sabeen Nadir, Scientist, Pfizer Inc. , Scientist , Pfizer Inc — Sabeen Nadir, Scientist, Pfizer Inc. , Scientist , Pfizer Inc

Photo of Lukas Bongers, PhD Student, Gene Therapy Technical R&D, Roche Diagnostics GmbH , PhD Student , Gene Therapy Technical R&D , Roche Diagnostics GmbH — Lukas Bongers, PhD Student, Gene Therapy Technical R&D, Roche Diagnostics GmbH , PhD Student , Gene Therapy Technical R&D , Roche Diagnostics GmbH

Photo of Thomas F. Johnson, PhD, Lecturer, Biochemical Engineering, University College London , Senior Research Fellow , Biochemical Engineering , University College London — Thomas F. Johnson, PhD, Lecturer, Biochemical Engineering, University College London , Senior Research Fellow , Biochemical Engineering , University College London

3D printed chromatography columns provide advantages over conventional packed bed resins, in particular, control over the multiscale structure that can be tailored to the needs of the separation. However, possible disparities between design and fabricated columns lessens this benefit. We apply 3D imaging to evaluate and compare printed structures to original CAD files to refine the design process, creating more effective separation capabilities for emergent biological products.